RT Journal Article
SR Electronic
T1 CX-072 (pacmilimab), a Probody<strong><sup>®</sup></strong> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002447
DO 10.1136/jitc-2021-002447
VO 9
IS 7
A1 Naing, Aung
A1 Thistlethwaite, Fiona
A1 De Vries, Elisabeth G.E.
A1 Eskens, Ferry A.L.M.
A1 Uboha, Nataliya
A1 Ott, Patrick A.
A1 LoRusso, Patricia
A1 Garcia-Corbacho, Javier
A1 Boni, Valentina
A1 Bendell, Johanna
A1 Autio, Karen A.
A1 Randhawa, Manreet
A1 Durm, Greg
A1 Gil-Martin, Marta
A1 Stroh, Mark
A1 Hannah, Alison L.
A1 Arkenau, Hendrik-Tobias
A1 Spira, Alexander
YR 2021
UL http://jitc.bmj.com/content/9/7/e002447.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.